Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the safety and efficacy of Liposomal
Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a
population undergoing PCI with implantation of a bare metal stent.
Study hypothesis: Liposomal Alendronate will reduce in-stent restenosis as compared to
placebo.
Phase:
Phase 2
Details
Lead Sponsor:
BIOrest Ltd.
Collaborators:
Baim Institute for Clinical Research Cardiovascular Research Foundation, New York Harvard Clinical Research Institute Stanford University